Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Speciality: Oncology

Description:

Welcome to this insightful discussion featuring Dr. Srinivas K G, as he breaks down the groundbreaking PALOMA-2 trial and its transformative impact on the treatment of HR+/HER2- metastatic breast cancer. In this video, Dr. Srinivas elaborates on how CDK4/6 inhibitors, such as palbociclib, have redefined therapeutic strategies, offering improved progression-free survival and quality of life for patients. He provides a detailed analysis of the trial’s findings, explaining the mechanism of CDK4/6 inhibitors and their role in combination with endocrine therapy.

Dr. Srinivas further explores the clinical implications of the PALOMA-2 study, highlighting how these inhibitors have become a cornerstone of first-line treatment for advanced breast cancer. He discusses key patient subgroups, efficacy data, and safety profiles, offering valuable insights for oncologists and healthcare professionals. The discussion also touches upon real-world evidence and future directions, including ongoing research to optimize CDK4/6 inhibitor use in different settings. 

We hope you find this deep dive into PALOMA-2 and CDK4/6 inhibitors both enlightening and practical. Stay tuned for more expert discussions with Dr. Srinivas K G, where we continue to explore the latest advancements in oncology and breast cancer care. Don’t forget to like, share, and subscribe for more updates on cutting-edge cancer treatments!
 

See More Webinars @ Hidoc Webinars